Mirrors of Medicine

"What's the most evidence-based decision for our patients?" With so much new data at #ESMO25, turning evidence into practice is more important than ever. Dr. Henning Plage shares why the Global Forum on GU Oncology is one his favourite meetings to attend. REGISTER NOW: https://lnkd.in/eUrVTQxw for 🔎Actionable insights for real-world practice 🔁Interactive sessions with live polling 💬 Case-based discussions 🌍 Multidisciplinary global faculty @OncoAlert #RENALC25 #BLADDR25 #PROSCA25

Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven https://lnkd.in/dBDf2ns5 Metastatic urothelial carcinoma (mUC) has long been associated with poor outcomes and limited therapeutic options, but recent advances in tumor biology have driven the emergence of innovative treatments such as immune checkpoint inhibitors and antibody-drug conjugates (ADCs). ADCs like enfortumab vedotin, sacituzumab govitecan, and trastuzumab deruxtecan have transformed the therapeutic landscape by enabling targeted cytotoxic delivery to tumor cells. This review explores the evolving role of ADCs in mUC, focusing on their mechanisms of action, clinical efficacy, patient selection, molecular insights, and the potential for personalized therapeutic strategies in this rapidly advancing field. #BladderCancer Alberto D’angelo  Martina Catalano

Immune Checkpoint Inhibitors Beyond Progression in Various Solid Tumors: A Systematic Review and Pooled Analysis https://lnkd.in/drn9jGVK Immune checkpoint inhibitors (ICIs) have revolutionized cancer care, yet the benefit of continuing treatment beyond radiologic progression remains unclear. In a systematic review of 50 studies encompassing 8,989 patients across multiple tumor types, continuation of ICIs after progression showed variable but notable efficacy, particularly in melanoma, non-small cell lung cancer, and renal cell carcinoma, with objective response rates up to 39% and median overall survival reaching 34.8 months in select cohorts. Modest benefits were also observed in gastrointestinal, head-and-neck, liver, and urothelial cancers. These findings suggest that a subset of patients can achieve meaningful disease control with ICI therapy beyond progression, though outcomes depend heavily on tumor biology, clinical context, and emerging biomarkers—underscoring the need for prospective, biomarker-driven trials to refine patient selection and treatment duration.  Antonio Ghidini   Giuseppina Patrizia Dognini Lorenzo Dottorini  alessandro iaculli 

With #ESMO25 approaching, we already look forward to our next webinar! Register now and join Dr. Fred Saad and Dr. Marc-Oliver Grimm in a discussion on triplet approaches for #mHSPC 📌Register here, it's free: https://lnkd.in/eDhN2tgZ OncoAlert

Tyrosine-kinase inhibitors for lung or breast cancer and drug–drug interactions: a clinical guide https://lnkd.in/dpFqxryy Over the past two decades, tyrosine-kinase inhibitors (TKIs) have significantly improved outcomes for lung and breast cancer patients, both in metastatic and selected adjuvant settings. Despite their efficacy, TKIs are prone to drug–drug interactions (DDIs) due to pH-dependent absorption and liver metabolism, though the clinical relevance of these interactions is often underestimated and practical guidance is limited. This narrative review of the last 20 years summarizes the pharmacokinetics and clinical evidence for 11 TKIs, offering a practical guide for clinicians on dose adjustments and precautions to minimize adverse events. While current evidence on DDIs is limited, largely derived from early-phase studies, awareness and proactive management are critical, and further large-scale prospective trials are needed to better define clinically relevant interactions. #LungCancer #BreastCancerAwareness Fiorenza Santamaria  Michela Roberto Andrea Torchia  Dorelsa Buccilli  Daniele Marinelli  Andrea Botticelli  Daniele Santini

"We will hear updates on the changing landscape of renal, bladder and prostate cancer and discuss how we integrate the new data into daily practice" 💬 Dr. Aurelius Omlin invites you to join us for expert insights and real-world discussions at #RENALC25, #BLADDR25 and #PROSCA25 🌟Don't miss out - register now: https://lnkd.in/e2Ydprqk OncoAlert

Histopathology and outcomes of non-metastatic renal cell carcinoma with inferior vena cava tumor thrombus: systematic review and meta-analysis https://lnkd.in/d7mUpktV Systematic review analyzes data from 19 studies on non-metastatic renal cell carcinoma (RCC) with inferior vena cava (IVC) thrombus, a challenging presentation that complicates both treatment and prognosis. While surgery remains the standard approach, the review highlights limited exploration of minimally invasive and systemic treatment options. Findings show that clear cell histology predominates, with survival outcomes varying significantly by histological subtype and thrombus extent. The study emphasizes the potential benefits of tailored strategies—such as neoadjuvant and adjuvant therapies—to optimize patient outcomes and calls for further research into personalized treatment protocols for RCC with IVC involvement. #KidneyCancer Savio Domenico Pandolfo Gabriele Bignante Angelo Orsini  Monica Rutigliano  Emanuele Naglieri  Riccardo Autorino MD PhD  Pasquale Pasquale Prof. Ditonno Giuseppe Lucarelli

Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial https://lnkd.in/dg5fNqfT In a multicenter, single-arm phase II trial, the bispecific antibody-drug conjugate BL-B01D1—targeting EGFR and HER3 and carrying the cytotoxic payload Ed-04—was evaluated in 41 patients with locally advanced or metastatic urothelial carcinoma refractory to prior systemic therapy. At the recommended 2.2 mg/kg dose, BL-B01D1 demonstrated an objective response rate of 44.1% and a disease control rate of 88.2%, with responses particularly notable (80%) among those who had received only one prior line of therapy. Median progression-free survival was 7.3 months, and median duration of response reached 11.3 months. The most common treatment-related toxicities included hematologic events such as anemia, leukopenia, and neutropenia, with manageable safety overall. These findings support BL-B01D1 as a promising therapeutic option for patients with heavily pretreated urothelial carcinoma. #BladderCancer

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium https://lnkd.in/dWGjYPdQ This study systematically reviewed 119 publications on neoadjuvant therapy in renal cell carcinoma (RCC) to evaluate how pathological response is currently assessed and reported. The analysis revealed that only 4% of studies detailed their response assessment methods, and just 7% employed quantitative measures, highlighting a lack of standardization. To address this, an international expert workshop at the Netherlands Cancer Institute in 2024 developed consensus recommendations for tissue preparation and response reporting. The proposed guidelines advocate for standardized specimen sampling, quantification of residual viable tumor in 10% intervals with measurement of greatest linear extent, and inclusion of clinical treatment details. These standardized methods aim to enable consistent evaluation of pathological response in RCC, facilitating research into its correlation with survival outcomes and paving the way toward uniform reporting in future clinical studies. #KidneyCancer James Blackmur  Femke Burgers  Michelle Hirsch Payal Kapur  Rohit Mehra  Priya Rao  Sabina Signoretti  Grant Stewart james jones

Which systemic treatment option would you choose for this mCRPC patient❓ 🗳️Vote here: https://lnkd.in/eVFVYyPC & 👀 See what Dr. Ananya Choudhury would do in a short video. Join more case discussions live in Lisbon or online by registering here for PROSCA 👉 https://lnkd.in/eEhTUFKV OncoAlert